Skip to Content
MilliporeSigma
All Photos(1)

Documents

1362103

USP

Levofloxacin

United States Pharmacopeia (USP) Reference Standard

Synonym(s):

Levofloxacin hemihydrate

Sign Into View Organizational & Contract Pricing
All Photos(1)

About This Item

Empirical Formula (Hill Notation):
C18H20FN3O4 · 0.5H2O
CAS Number:
138199-71-0
Molecular Weight:
370.38
MDL number:
MFCD07772024
UNSPSC Code:
41116107
PubChem Substance ID:
329750045
NACRES:
NA.24

grade

pharmaceutical primary standard

API family

levofloxacin

manufacturer/tradename

USP

application(s)

pharmaceutical (small molecule)

format

neat

SMILES string

O.C[C@H]1COc2c(N3CCN(C)CC3)c(F)cc4C(=O)C(=CN1c24)C(O)=O.C[C@H]5COc6c(N7CCN(C)CC7)c(F)cc8C(=O)C(=CN5c68)C(O)=O

InChI

1S/2C18H20FN3O4.H2O/c2*1-10-9-26-17-14-11(16(23)12(18(24)25)8-22(10)14)7-13(19)15(17)21-5-3-20(2)4-6-21;/h2*7-8,10H,3-6,9H2,1-2H3,(H,24,25);1H2/t2*10-;/m00./s1

InChI key

SUIQUYDRLGGZOL-RCWTXCDDSA-N

Looking for similar products? Visit Product Comparison Guide

Related Categories

Application

Levofloxacin USP Reference standard, intended for use in specified quality tests and assays as specified in the USP compendia. Also, for use with USP monographs such as:
  • Levofloxacin Tablets
  • Levofloxacin Oral Solution

Analysis Note

These products are for test and assay use only. They are not meant for administration to humans or animals and cannot be used to diagnose, treat, or cure diseases of any kind.  ​

Other Notes

Sales restrictions may apply.

related product

Product No.
Description
Pricing

1362114

Levofloxacin Related Compound A, United States Pharmacopeia (USP) Reference Standard

1362125

Levofloxacin Related Compound B, United States Pharmacopeia (USP) Reference Standard

1362136

Levofloxacin Related Compound C, United States Pharmacopeia (USP) Reference Standard

1362169

Levofloxacin Related Compound F, United States Pharmacopeia (USP) Reference Standard

1362158

Levofloxacin Related Compound E, United States Pharmacopeia (USP) Reference Standard

Y0002085

Levofloxacin hemihydrate, European Pharmacopoeia (EP) Reference Standard

Y0002084

Levofloxacin impurity F, European Pharmacopoeia (EP) Reference Standard

Y0002089

Levofloxacin for system suitability, European Pharmacopoeia (EP) Reference Standard

PHR2229

Levofloxacin Related Compound B, Pharmaceutical Secondary Standard; Certified Reference Material

PHR2230

Levofloxacin Related Compound C, Pharmaceutical Secondary Standard; Certified Reference Material

pictograms

Health hazardExclamation mark
GHS08,GHS07

signalword

Danger

Hazard Classifications

Acute Tox. 4 Oral - Resp. Sens. 1 - Skin Sens. 1

Storage Class

11 - Combustible Solids

wgk_germany

WGK 3

flash_point_f

Not applicable

flash_point_c

Not applicable

Certificates of Analysis (COA)

Search for Certificates of Analysis (COA) by entering the products Lot/Batch Number. Lot and Batch Numbers can be found on a product’s label following the words ‘Lot’ or ‘Batch’.

Already Own This Product?

Find documentation for the products that you have recently purchased in the Document Library.

Visit the Document Library

R Davis et al.
Drugs, 47(4), 677-700 (1994-04-01)
Levofloxacin, an oral fluoroquinolone antibacterial agent, is the optical S-(-) isomer of ofloxacin. In vitro it is generally twice as potent as ofloxacin. Levofloxacin is active against most aerobic Gram-positive and Gram-negative organisms and demonstrates moderate activity against anaerobes. Drug
Analysis and Standardization of Levofloxacin Substance.
Sedova, M. K., et al.
Pharmaceutical Chemistry Journal, 47.11, 620-626 (2014)
Sabine Schuster et al.
Antimicrobial agents and chemotherapy, 58(11), 6870-6878 (2014-09-04)
Efflux is an important mechanism of bacterial multidrug resistance (MDR), and the inhibition of MDR pumps by efflux pump inhibitors (EPIs) could be a promising strategy to overcome MDR. 1-(1-Naphthylmethyl)-piperazine (NMP) and phenylalanine-arginine-β-naphthylamide (PAβN) are model EPIs with activity in
Lixian He et al.
Anti-cancer drugs, 26(3), 359-362 (2014-12-09)
This pilot study assesses the safety and efficacy of once-daily, oral levofloxacin monotherapy in Chinese patients with low-risk febrile neutropenia. In this prospective, single-arm, open-label, multicenter clinical trial, 46 adult Chinese patients with solid tumors and low-risk febrile neutropenia were
Kyoko Yamazoe et al.
Cornea, 33(11), 1157-1163 (2014-09-26)
The aim of this study was to investigate the efficacy and safety of systemic tacrolimus for the treatment of eyes that developed graft failure despite treatment with cyclosporine (CsA). Ten eyes of 10 patients who underwent high-risk penetrating keratoplasty (PKP)
View All Related Papers

Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.

Contact Technical Service